Guest Editors
Prof. Michał Zarobkiewicz
Email: michal.zarobkiewicz@umlub.pl
Affiliation: Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland
Homepage: https://umlub.pl/uczelnia/pracownicy/szczegoly,4476.html; http://www.gammadelta.pl/
Research Interests: flow cytometry, tumour immunology, autoimmunity, γδ T cells
Dr. Natalia Lehman
Affiliation: Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, 20-093 Lublin, Poland
Email: lehmannatalia8@gmail.com
Research Interests: tumor immunology, γδ T cells, iNKT cells, checkpoint molecules, cytotoxicity-related receptors
Summary
This special issue seeks original research and review articles on the roles of γδ T cells and invariant natural killer T (iNKT) cells in malignancies. Emphasis is placed on their clinical importance, prognostic value, and potential therapeutic applications. Submissions addressing the expression of checkpoint molecules (e.g., PD-1, TIGIT) and cytotoxicity-related receptors (e.g., NKG2D, DNAM-1, CD16) on these cells are highly encouraged. Studies examining how various treatments affect γδ T cells and iNKT cells are also welcome. Additionally, research on butyrophilins, which are crucial for γδ T cell activation, and CD1d, which plays a central role in iNKT cell activation, is of particular interest. This issue aims to deepen the understanding of these immune cells in cancer biology and their therapeutic potential.
We invite submissions on the following topics:
1. Biological Properties and Functions
• Characteristics, immune functions, and tumor recognition mechanisms of γδ T cells and iNKT cells.
• Activation pathways and antigen recognition contributing to immune surveillance.
2. Tumor Microenvironment
• Distribution, function, and dysfunction of γδ T and iNKT cells in malignancies.
• Immune evasion strategies by tumors and their impact on immune responses.
3. Therapeutic Potential and Challenges
• Immunotherapies and cell-based therapies (e.g., CAR-T) involving γδ T and iNKT cells.
• Addressing challenges like immune exhaustion, persistence, and trafficking.
4. Immune Checkpoints and Immunomodulation
• Roles of PD-1, TIGIT, and other checkpoint molecules in regulating γδ T and iNKT cells.
• Combining immune checkpoint inhibitors with γδ T and iNKT cell therapies.
5. Clinical Data and Translational Strategies
• Clinical trial data and outcomes for γδ T and iNKT cell therapies in cancer.
• Translating preclinical research into effective clinical applications.
6. Emerging Technologies and Future Directions
• Use of single-cell sequencing, CRISPR, and advanced profiling in studying these cells.
•Strategies to enhance cell-based therapies, targeting immune evasion, and new molecular targets.
Keywords
γδ T cells, iNKT cells, cancer, immunotherapy, tumor microenvironment, immune evasion, molecular mechanisms, cellular therapies
Login
Register
Submit a Paper
Propose a Special lssue
